About us
We provide knowledge to decisions.
IDL Diagnostics is a Swedish diagnostics company
with the vision to improve the monitoring of oncological and bacterial diseases. We have a broad product portfolio of IVD tests that deliver high-value clinical information for the detection of disease with indications spanning everything from urological cancers to typhoid fever. IDL Diagnostics targets different patient groups in different parts of the world.
Based on our proprietary technologies
and our biomarkers, we develop tests that are clinically useful and economically viable, making us a valuable and relevant diagnostic partner for healthcare professionals. We provide rapid tests, laboratory tests and platform tests that improve decision making and are non-invasive, cost effective, and easy to perform – all of which are important criteria for the healthcare and payer community.
At IDL Diagnostics, we are proud that our diagnostic solutions
can contribute to one of the ‘three imperatives’ for reducing the burden of disease: diagnostics, therapeutics and vaccines. In the wake of covid-19, it is fair to say that diagnostics has been given a well-deserved place in the healthcare limelight. With a growing number of elderly people around the world in combination with an increase in the incidence of chronic diseases, the need for accurate diagnostics is essential.
We create value for our shareholders
by executing our strategy of increasing sales volumes in existing markets, obtaining market approvals in other prioritized markets, and continuously developing the next generation of IVD tests. With a pipeline that meets current and future demands, we stay relevant not only to patients, but to all our stakeholders. IDL Diagnostics was first listed in 2016 and our shares are traded on Stockholm Nasdaq First North.
With an organization that occupies the entire value chain
from R&D to manufacturing and marketing, we have the flexibility of a small company and the characteristics of a big company. It enables us to be a fast mover in the fast growing field of IVD-tests This is critical for us to be able deliver on our vision to be valuable and relevant diagnostic partner in oncology healthcare.
A word from the CEO
Dear friends!
Taking on the role of CEO at IDL Diagnostics is both an honour and a responsibility that I approach with great enthusiasm. Having been part of the company for many years, I have had the opportunity to be part of its development from a focused diagnostics player to a company with a strong platform for international growth. This long-term perspective gives me deep confidence in both our capabilities and our future. I look forward to leading IDL Diagnostics into its next phase of development, building on the solid foundation that has already been established.
A strong foundation for growth
Over the years, IDL Diagnostics has been carefully shaped into a stable and resilient organization. We have developed robust internal processes, built a high-quality product portfolio, and established a culture defined by scientific integrity and commercial focus. This foundation is critical, as it allows us to scale effectively while maintaining operational discipline. It also positions us to respond quickly to opportunities in a fast-changing diagnostics landscape.
Strategic partnerships driving expansion
In recent years, we have entered several important collaborations that we believe will be instrumental in driving future growth. Notably, our partnerships within the Chinese market for automated CLIA platforms represent a significant step in expanding access to high-throughput diagnostic solutions. At the same time, our collaboration with concile global in the rapid test segment provides us with a strong commercial channel into point-of-care settings. Together, these partnerships form key pillars of our growth strategy and enable us to leverage both technological innovation and market reach.
A network of partners enabling future potential
Beyond these agreements, we have a network of key partners across different geographies and segments. These relationships are built on mutual trust and a shared vision of advancing diagnostic solutions. We believe that this partner ecosystem will act as a catalyst for the continued expansion of our existing product portfolio, while also supporting the successful introduction of new offerings. Collaboration will remain central to how we create value going forward.
A favourable and evolving market landscape
The outlook for the diagnostics market is increasingly positive. We are seeing a growing recognition of the importance of early detection, monitoring, and precision diagnostics among healthcare providers and decision-makers. At the same time, there is a broader acceptance of innovative testing solutions. This shift aligns well with our portfolio and capabilities, and we believe it will translate into increased demand for our products across multiple markets.
On track for sustainable growth and profitability
Our strategic direction is clear: to deliver sustainable and profitable growth over time. We are confident that we are on the right path to achieving this. By combining a strong operational base, targeted partnerships, and strong market support, we are well positioned to strengthen our financial performance while continuing to invest in future opportunities.
In closing, I would like to thank our employees, partners, and shareholders for their continued trust and commitment. Together, we have built a company with significant potential. I am convinced that the most exciting chapters of our journey still lie ahead.
Thank you for being part of IDL Diagnostics!
Gustav Sten, CEO of IDL Diagnostics
Investors
We are listed on NASDAQ First North Growth Market.
We want to be the obvious choice within our segment in the markets where we are established. The market for our products is large and we are a smaller player with significant growth potential so far. IDL Diagnostics is unique for a company of this size.
Bacteriology
An effective typhoid test
Typhoid fever is water and food-borne infectious disease caused by the bacterium, Salmonella enterica. IDL Biotechs product TUBEX® TF, is a rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever.
Oncology
Diagnostics for oncology
Cancer is one of the leading causes of death worldwide, despite advancing knowledge. To improve cancer patient management, there is a clear need for efficient diagnostics tools to capture this critical clinical data.
